Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02097823 · ClinicalTrials.gov registry record · Phase 2
Pilot Study of Olanzapine and Aprepitant to Prevent Nausea and Vomiting in Children Receiving Chemotherapy
A Phase 2 study, sponsored by Indiana University.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT02097823 is a Phase 2 study that has completed, run by Indiana University. The registered enrollment target is 15 participants.
The verdict
NCT02097823, a Phase 2 study, has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the feasibility of a larger trial comparing olanzapine and aprepitant and to obtain preliminary data on the effectiveness of these two medications to treat nausea and vomiting in children receiving chemotherapy. Children receiving 2 cycles of chemotherapy with a high risk of causing nausea and vomiting will receive olanzapine in one cycle and aprepitant in another cycle. Children will be randomized to see which medicine they receive first. The investigators will record the number of extra medications used for nausea, the number of times a child vomits, and the amount of nausea the child feels each day.
Interventions
- DRUG Olanzapine
- DRUG Aprepitant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2014-02 |
| Est. Completion | 2015-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02097823
The ClinicalTrials.gov registry entry for NCT02097823 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Indiana University, which has 890 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Olanzapine is the first listed.
NCT02097823 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02097823 about?
NCT02097823 is a clinical study titled "Pilot Study of Olanzapine and Aprepitant to Prevent Nausea and Vomiting in Children Receiving Chemotherapy". The purpose of this study is to determine the feasibility of a larger trial comparing olanzapine and aprepitant and to obtain preliminary data on the effectiveness of these two medications to treat nausea and vomiting in children receiving chemotherapy. Children receiving 2 cycles of chemotherapy wi...
What is the current status of trial NCT02097823?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2014-02. Estimated completion is 2015-03.
What interventions are being tested in trial NCT02097823?
The interventions under investigation include: Olanzapine (DRUG), Aprepitant (DRUG).
Who is sponsoring clinical trial NCT02097823?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.